IRIDEX Corporation — Q1 2015 Form 10-Q
Reporting period: 13 weeks ended April 4, 2015; comparisons are with the 13 weeks ended March 29, 2014. IRIDEX develops, manufactures and sells ophthalmic laser systems, delivery devices, consumables, and related services.
Financial performance
| Metric | Q1 2015 | Prior-year quarter | Change |
|---|---|---|---|
| Revenue | $10.796 million | $10.329 million | +4.5% |
| Gross profit / margin | $5.410 million / 50.1% | $5.055 million / 48.9% | Margin +1.2 points |
| Operating expenses | $5.007 million | $4.458 million | +12.3% |
| Operating income / margin | $403,000 / 3.7% | $597,000 / 5.7% | Down 32.5% |
| Net income / diluted EPS | $246,000 / $0.02 | $487,000 / $0.05 | Net income down 49.5% |
| Cash from operations | $617,000 | $645,000 | Down $28,000 |
Revenue growth reflected domestic system sales and recurring revenue, including the February launch of the Cyclo G6 glaucoma platform. Domestic system revenue increased 24.6% to $2.081 million; international system revenue fell 8.7% to $3.497 million; recurring revenue rose 8.1% to $5.218 million. Management attributed the weakness in international system sales partly to foreign-currency effects. The United States generated 51.7% of revenue; international sales were 48.3%.
Gross margin improved primarily due to manufacturing variances and better direct margins, partly offset by higher manufacturing overhead, including one-time expenses. Operating expenses increased, particularly sales and marketing (+18.5%), reflecting commissions, selling costs, and marketing headcount and spending. Higher taxes also weighed on earnings: the $150,000 provision compared with $13,000 a year earlier; the effective tax rate was 37.9% versus 2.6%, as the prior-year quarter included a valuation-allowance effect. The company released $9.2 million of deferred-tax valuation allowance in Q4 2014.
Financial position and cash flows
At April 4, 2015, cash and cash equivalents were $13.122 million, working capital was $26.0 million, total assets were $42.250 million, and total liabilities were $8.240 million. Current assets were $33.210 million and current liabilities $7.214 million. The filing reports no outstanding fixed- or variable-rate debt. Cash declined $181,000 during the quarter. Operating cash flow of $617,000 was offset by $493,000 of investing outflows and $305,000 of financing outflows. Capital expenditures were $397,000; financing included $600,000 of payroll withholding taxes on net-settled equity awards, $192,000 of share repurchases, and $487,000 of option-exercise proceeds.
Inventory increased $735,000, primarily in preparation for the Cyclo G6 launch. Contractual obligations totaled $11.279 million, including $9.484 million of purchase commitments and $1.795 million of operating lease payments; $8.281 million was due within one year. Management stated that cash and expected operating cash flows were sufficient to operate for the next 12 months.
Outlook, risks, and notable items
- No quantitative revenue or earnings guidance was provided. Management discussed anticipated sales, product adoption, margins, growth, investment, and liquidity as forward-looking matters, subject to risks and without a commitment to update projections.
- Management cautioned that results can fluctuate with sales mix, seasonality, product acceptance, shipment timing, manufacturing efficiency, and costs. The company highlighted competition, international distributor dependence and currency-related competitiveness, reimbursement uncertainty, regulatory requirements, and reliance on sole- or limited-source suppliers.
- The Cyclo G6 launch is a strategic move intended to expand participation in glaucoma capital-equipment and recurring probe sales; launch-related inventory investment increased during the quarter.
- The earn-out liability was $1.335 million, measured using Level 3 assumptions, including projected royalties and discount rates. The quarter included an $8,000 fair-value expense and $96,000 of earn-out payments.
- Unrecognized tax benefits were $0.9 million. Management reported no ordinary-course legal matters expected to have a material adverse effect, and no material subsequent events. Disclosure controls were assessed as effective; no material change in internal control was reported.
- The company repurchased 21,539 shares for $192,000 and had approximately $717,000 of authorization remaining. It withheld 66,365 shares and paid approximately $600,000 in employee tax obligations related to released restricted stock units.
Important facts for investors to verify
- Whether Cyclo G6 adoption translates into sustained system sales and recurring probe revenue.
- Whether gross-margin improvement persists while operating expenses continue to rise.
- International system-sales trends, distributor performance, and exposure to currency-driven competitiveness.
- Inventory levels, purchase commitments, and cash generation relative to the company’s 12-month liquidity assessment.
- Assumptions underlying the earn-out liability and realization of deferred tax assets, including the $0.9 million of unrecognized tax benefits.